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ABSTRACT
Approximately 5-10% of cancers are thought to be hereditary, caused by
pathogenic variants in genes associated with inherited cancer syndromes. Previvors,
individuals who have a higher predisposition to cancer due to genetic or other risk
factors, have specific healthcare and psychological needs that may be better served by a
specialized management clinic. This study compared the experiences of previvors who
had access to a specialized management clinic with those who did not, in order to better
understand the unique needs of previvors. This study utilized a mixed methods design
including an online survey (N=26) and semi-structured phone interview (N=6). Overall,
previvors with access to a specialized management expressed a reduction in stress level
(N=5), expedited necessary medical care (N=2), access to a simplified clinical process
(N=5), and provision of information needed to make informed decisions regarding their
medical care (N=8). Previvors who did not have access to a specialty clinic described
challenges with finding information about their risk (N=4), receiving care from general
practitioners (N=3), and having questions unanswered by healthcare providers (N=6),
further supporting previous literature that investigated the nuanced care required by
previvors. Previvors without access to a management clinic desired a team of specialists
familiar with genetics, a forum to ask questions, and a clinic that would ensure their care
meets the current recommendations. This study demonstrates the need for specialized
management clinics designed with previvors’ needs in mind in order to provide these
patients with the most appropriate care.
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CHAPTER 1: BACKGROUND AND LITERATURE REVIEW
1.1 Hereditary Cancer
Approximately 5-10% of cancers are thought to be hereditary. Hereditary cancer
is caused by mutations in genes associated with hereditary cancer syndromes, and a
pathogenic mutation results in a significantly increased risk for cancer development
compared to that of the average population (Senter & Hatfield, 2016). Mutations that
cause hereditary cancer syndromes are identified through the use of genetic testing,
specifically testing that targets oncogenes and tumor suppressor genes, genes associated
with regulation of cell growth and hereditary cancer (Dekanek et al., 2019). Once a
pathogenic mutation has been identified, it is recommended that the patient pursue
management specific to their cancer risks, often as directed by the guidelines established
by the National Comprehensive Cancer Network (NCCN), a society recognized in the
medical community to be an authority on cancer care (NCCN, 2020).
There are a large number of genes associated with hereditary cancer. This study
encompassed individuals with mutations in ATM, BRCA1, BRCA2, CDH1, CHEK2,
PALB2, PTEN, and TP53. While these genes are mainly associated with breast cancer,
mutations in them also carry other cancer risks. In addition, these genes have specific
management recommendations established by NCCN that aid in patient care. The cancer
risks for each gene are shown in Table 1.1 below (adapted from GeneReviews (2016);
National Comprehensive Cancer Network (NCCN), 2020).
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Table 1.1 High-Risk Breast Cancer Genes and Associated Cancer Risks
Gene
Cancer Risks
ATM
Breast (15-40%)
Pancreatic (5-10%)
Ovarian (<3%)
Prostate
BRCA1 Breast, with predisposition to triple negative disease (>60%)
Ovarian (39-58%)
Male breast
Prostate
Pancreatic (≤ 5%)
BRCA2 Breast, with predisposition to ER+ disease (>60%)
Ovarian (13-29%)
Male breast
Prostate
Pancreatic (5-10%)
Melanoma (elevated)
CDH1 Breast, with predisposition to lobular disease (41-60%)
Diffuse gastric
CHEK2 Breast, with predisposition to ER+ disease (15-40%)
Colon
Prostate
Stomach
Sarcoma
Kidney
PALB2 Breast (41-60%)
Ovarian (3-5%)
Male breast
Pancreatic (5-10%)
PTEN Breast (40-60%, may be >60%)
Thyroid
Renal cell
Endometrial
Colorectal
TP53
Breast (>60%)
Pancreatic (5-10%)
Soft tissue sarcoma
Osteosarcoma
Brain tumors
Adrenocortical carcinoma
Leukemia
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1.2 Genetic Testing Recommendations for Hereditary Cancer
Genetic testing for hereditary cancer syndromes is recommended for individuals
who meet certain criteria as determined by NCCN. One example of this criteria is the
NCCN Testing Criteria for High-Penetrance Breast and/or Ovarian Cancer Susceptibility
Genes. If criteria are met and no known familial mutation has been identified, providers
should consider comprehensive testing for the patient with a multi-gene panel (NCCN,
2020). NCCN (2020) recommends genetic testing for hereditary breast and ovarian
cancer for the following indications, listed in Table 1.2 below (adapted from NCCN,
2020).
Table 1.2 NCCN Testing Criteria for High-Penetrance Breast/Ovarian Cancer
Susceptibility Genes
NCCN Testing Criteria for High-Penetrance Breast/Ovarian Cancer
Susceptibility Genes
1. Any blood relative with a pathogenic/likely pathogenic variant in a cancer
susceptibility gene
2. Personal history of breast cancer under age 45 or age 46-50 with a second breast
cancer at any age or at least one close relative with breast, ovarian, pancreatic, or
prostate cancer at any age
3. Personal history of triple negative breast cancer at age 60 or younger
4. Personal history of breast cancer at any age with Ashkenazi Jewish ancestry or a
close relative with breast cancer under age 50, ovarian, pancreatic, or metastatic
prostate cancer at any age
5. Diagnosis of male breast cancer at any age
6. Diagnosis of epithelial ovarian cancer (including fallopian tube cancer or peritoneal
cancer) at any age
7. Diagnosis of exocrine pancreatic cancer at any age
8. Diagnosis of prostate cancer at any age with metastatic, intraductal/cribriform
histology, or high- or very-high-risk group
9. Diagnosis of prostate cancer of any NCCN risk group with Ashkenazi Jewish
ancestry, one or more close relatives with breast cancer under age 50, ovarian,
pancreatic, or metastatic, or intraductal/cribriform prostate cancer at any age, or 2 or
more close relatives with either breast or prostate cancer (any grade) at any age
10. A mutation was identified on tumor genomic testing that has clinical implications if
identified in the germline
11. Meets Li-Fraumeni Syndrome testing criteria, Cowden syndrome/PTEN hamartoma
syndrome testing criteria
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12. To aid in systemic therapy decision-making, such as for HER2-negative breast
cancer
13. An affected or unaffected individual with a first- or second- degree relative meeting
any of the above
14. An affected or unaffected individual who otherwise does not meet the criteria above
but has a probability >5% of a BRCA1/2 pathogenic variant based on prior
probability models (e.g., Tyrer-Cuzick, BRCAPro, Can Risk)
1.3 Previvorship
By meeting the first or thirteenth criterion described above, and pursing testing
for a known familial variant or because of a family history of cancer, individuals are
learning of their previvor status (NCCN, 2020). The term previvor was initially coined by
the advocacy group, Facing Our Risk of Cancer Empowered (FORCE), and is used to
describe individuals “who have a much greater predisposition to cancer than individuals
in the general population but who have not yet developed the disease” (Carvalho et al.,
2019, p. 1). Increase in the identification of previvors can be attributed to increased
interest in genetic testing, increased testing of ovarian cancer patients who may be
candidates for PARP (poly ADP-ribose polymerase) inhibitor therapies, and the
identification of relatives of these patients who may be at risk for carrying these
mutations (Carvalho et al., 2019). This greater susceptibility may be due to the presence
of a pathogenic mutation in a hereditary cancer gene, increasing the risk for cancer, or
could be caused by other factors including family history (Getachew-Smith et al., 2019).
It has been recognized that individuals falling within the previvor category have “specific
psychosocial and healthcare needs…to help them decide how to manage this substantial
risk” (Mahon, 2014, p. 21).
Getachew-Smith et al. (2019) studied patients’ perceptions of the term previvor
and whether or not that identity resonated with them. Although FORCE established a
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definition for what constitutes a previvor, individuals who fall into that category had two
main distinctions in their definition. One group identified previvors as those with a
positive genetic test result, while the other group only considered previvors to be those
that have undergone some form of risk reducing surgery, either mastectomy or
oophorectomy. When assessing whether or not individuals accepted the term, they found
that the majority accepted the label, claiming that the term previvor gave them a sense of
community and validated their experience. However, some rejected the term due to its
similarity to the word “survivor,” and felt that perhaps the label diminished the
experience of cancer survivors. Some also felt that the term invoked fear, making it sound
as if cancer was inevitable (Getachew-Smith et al., 2019). Although there is no clear
consensus on the use of the term previvor, it is clear individuals within this category have
unique challenges.
1.4 Genetics-Based Management
Individuals with mutations in hereditary cancer genes have specific management
recommendations established by NCCN, but recommendations differ slightly from gene
to gene. In general, breast cancer screenings begin earlier than for women of average risk,
and for some mutations, a risk-reducing surgery, such as a mastectomy or salpingooophorectomy, may be considered. Because cancer risks vary from gene to gene, it is
important to know the patient’s carrier status when determining a management plan.
Table 1.3 outlines recommendations for each gene, adapted from the NCCN guidelines
(NCCN, 2019).
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Table 1.3 NCCN Management Recommendations for Hereditary Cancer Predisposition
Gene
Management Recommendations
ATM Annual mammogram, consider breast MRI at age 40
Risk-reducing mastectomy or salpingo-oophorectomy based on family
history
Pancreatic cancer screening (MRCP and EUS) starting at age 50 if family
history of pancreatic cancer
BRCA1 Breast awareness at age 18
Clinical breast exam every 6-12 months, beginning at age 25
Annual breast MRI from age 25 to 29
Annual mammogram with or without tomosynthesis from age 30 to 75
Consider risk-reducing mastectomy
Recommend salpingo-oophorectomy, typically between age 35-40
BRCA2 Breast awareness at age 18
Clinical breast exam every 6-12 months, beginning at age 25
Annual breast MRI from age 25 to 29
Annual mammogram with or without tomosynthesis from age 30 to 75
Consider risk-reducing mastectomy
Recommend salpingo-oophorectomy, no later than age 40-45
CDH1 Annual mammogram, consider breast MRI at age 30
Prophylactic gastrectomy between ages 18 and 40 and baseline endoscopy
Risk-reducing mastectomy based on family history
CHEK2 Annual mammogram, consider breast MRI at age 40
Colonoscopy every 5 years, beginning at age 40, or 10 years prior to firstdegree relative’s age at diagnosis
PALB2 Annual mammogram, consider breast MRI at age 30
Discuss option of risk-reducing mastectomy
Risk-reducing salpingo-oophorectomy based on family history
Pancreatic cancer screening (MRCP and EUS) starting at age 50 if family
history of pancreatic cancer
PTEN Breast awareness at age 18
Clinical breast exam every 6-12 months, starting at age 25 or 10 years before
diagnosis of breast cancer in family (whichever comes first)
Annual mammogram, consider breast MRI at age 30-35 (or 10 years before
diagnosis in family) until age 75
Discuss option of risk-reducing mastectomy
Consider endometrial biopsy every 1-2 years, starting age 35
Consider hysterectomy upon completion of childbearing
Annual physical exam, starting age 18 (or 5 years prior to first cancer
diagnosis)
Annual thyroid ultrasound, starting age 7
Colonoscopy starting age 35, every 5 years if negative (start earlier if family
history)
Consider renal ultrasound at age 40, every 1-2 years
Routine dermatology evaluation
Consider psychomotor assessment and brain MRI if symptoms present
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TP53

Breast awareness at age 18
Clinical breast exam every 6-12 months, starting age 20
Breast MRI age 20-29, MRI and mammogram age 30-75
Discuss risk-reducing mastectomy
Physical exam and neurological evaluation in cancer survivors every 6-12
months
Colonoscopy and upper endoscopy every 2-5 years, starting age 25 (or
earlier if family history)
Annual dermatologic evaluation, starting age 18
Annual whole-body MRI
Annual brain MRI
Pancreatic cancer screening (MRCP and EUS) starting at age 50 if family
history of pancreatic cancer

1.5 Management for Patients at High Risk of Breast Cancer
Some previvors may have a predisposition to cancer not due to a genetic
mutation, but rather due to family history or other factors (Getachew-Smith et al., 2019).
Several verified risk models exist to determine lifetime risk for breast cancer, including
Tyrer Cuzick, Gail, BRCAPRO, Claus, and BOADICEA. These models take into account
family history of breast and/or ovarian cancer, age, breast density, reproductive history,
hormonal history, genetic testing, and history of abnormal breast imaging or pathology to
calculate a lifetime risk for breast cancer (Monticciolo et al., 2018).
Women with a lifetime risk of breast cancer greater than or equal to 20% as
determined by these models are recommended to have additional screening, similar to
that of individuals with a genetic mutation that increases breast cancer risk (Monticciolo
et al., 2018). Table 1.4, below, adapted from NCCN (2021), outlines the recommended
management strategies for high-risk individuals:
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Table 1.4 NCCN High-Risk Breast Cancer Screening Guidelines
High-Risk Management
Breast awareness
Clinical encounter every 6-12 months (not to be started before age 21)
Annual screening mammogram
• 10 years prior to age of youngest breast cancer diagnosis in family
• Not to be started before age 30
• Consider tomosynthesis
Recommend annual breast MRI
• 10 years prior to age of youngest breast cancer diagnosis in family
• Not to be started before age 25
Recommend risk-reducing strategies
• Limit alcohol consumption
• Increase physical activity
• Weight control
• Breastfeeding
• Consider risk-reducing agents (tamoxifen, raloxifene, aromatase inhibitors)
Tamoxifen is a risk-reducing agent recommended for individuals at an increased
risk for breast cancer. NCCN currently recommends women age 35 or older may take 20
milligrams per day for five years and doing so can reduce breast cancer risk up to 49%
(NCCN, 2020). For individuals who have a history of atypical hyperplasia, taking
tamoxifen may reduce breast cancer risk by up to 89% (NCCN, 2020). Because of its
efficacy, NCCN recommends the use of tamoxifen in the reduction of breast cancer risk
for women at increased risk (NCCN, 2020).
1.6 Adherence to Management Recommendations
There is little data on how previvors are conducting cancer screening and
management or how closely they are following the NCCN screening guidelines.
However, in a study by Hesse-Biber and An (2016), researchers looked at surgical
decision-making among BRCA-positive individuals. The main factors that went into
surgical decision-making included age, parental status, gender of the children, level of
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psychological distress from the BRCA result, perceived family support, experienced
medical uncertainty, and the level of guilt they felt about the possibility of their children
inheriting the mutation. Interestingly, women who experienced more distress related to
their BRCA result, those who felt they lacked support from their family, and those who
perceived more medical uncertainty were more likely to choose surveillance rather than
surgery (Hesse-Biber & An, 2016). While the study looked at factors influencing their
management choices, they did not look into how closely surveillance was being followed.
Another study, by Hoskins, Roy, and Greene (2012), analyzed patients’ risk
perception of their BRCA1 or BRCA2 mutation. In their study of 60 participants, 17 had
already undergone a risk-reducing mastectomy and eight had an oophorectomy. An
additional 34 participants were either considering or concretely planning a risk-reducing
mastectomy and 45 were either considering or concretely planning a risk-reducing
oophorectomy. The authors concluded that many previvors may initially choose to
manage with increased surveillance before electing to proceed with a risk-reducing
surgery (Hoskins et al., 2012). Again, this study did not explore what screening these
participants were doing in place of risk-reducing surgery, suggesting that further research
in this area is needed.
1.7 Psychosocial Needs of Previvors
Individuals with a predisposition to cancer have unique needs compared to the
average population. In a study by Dean and Davidson (2018), it was found that these
individuals may have increased levels of uncertainty compared to those at average risk
for cancer. In fact, researchers found that previvors experience high levels of uncertainty,
and increased uncertainty can result in “emotional distress, anxiety, depression, loss of
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control, and poor decision making and quality of life” (p. 122). In order to manage this
uncertainty, previvors make decisions based on their perceived risk and available
information, so it is imperative that these individuals are receiving accurate information
and support (Dean & Davidson, 2018).
Furthermore, Mahon (2014) found that, although some online organizations and
support groups are available, many of these individuals feel isolated, as if no one else
understands what they are going through. They may feel as if they are being labeled or
feel “different from those who do not carry a mutation” (Mahon, 2014, p. 22). Many
times, support organizations help patients advocate for themselves, an important task as
they pursue surveillance and management. Previvors have described their experience
with their healthcare providers as overwhelming and exhausting because they have been
tasked with teaching their providers about their risk and management instead of receiving
the empathy and psychosocial support they need (Dean & Davidson, 2018).
These individuals are even faced with opposition to their decision to select riskreducing surgery to reduce cancer risk, with the opposing individuals claiming that
prophylactic surgery is too extreme. And even if supported in their decision to pursue
prophylactic surgery, these individuals face unique challenges as a result of their surgery.
Some women, after a risk-reducing mastectomy, have self-image difficulties and lack of
security in their identity (Mahon, 2014). After a risk-reducing salpingo-oophorectomy,
women may experience altered self-image, increased depression, increased fatigue, sleep
deprivation, and sexual dysfunction that can change her desire for intimacy and
ultimately affect personal relationships (Alexandre et al., 2017).
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Although much of a previvor’s uncertainty may arise from the potential to
develop cancer, previvors are also concerned about the impact their risk has on other
family members. In a study assessing perspectives of young adults at risk to have a
BRCA mutation, many participants emphasized the need for information about
reproductive issues and family planning (Young et al., 2019). Furthermore, in a study by
Dean and Rauscher (2017), it was observed that many women who are previvors use two
types of decision-making styles when thinking about family planning: logical and
emotional. Logical decision-making involved planning timing for undergoing riskreducing surgeries and processing the pressure from healthcare providers to receive
prophylactic care. Emotional decision-making involved processing her biological time
clock, her hopes for the future, guilt associated with children possibly inheriting the
mutation, and consideration of pre-implantation genetic diagnosis (Dean & Rauscher,
2017). For example, a woman must weigh the option of breastfeeding her child or
reducing her cancer risk with prophylactic mastectomy. In addition, previvors may be
worried about the risk to their children and when to communicate that risk (Mahon,
2014).
1.8 Utility of a Specialized Management Clinic
These unique needs of previvors and high-risk breast cancer patients support the
necessity of a specialty clinic for previvor management. As described above,
management for previvors and high-risk breast cancer patients is complex and variable,
thus it is imperative that individuals are managed by healthcare professionals who are
knowledgeable about the personalized care required. Studies have shown that obstetrics
and gynecology providers (OB/GYN) and family practice providers are not able to give
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previvors optimal care, primarily due to a lack of confidence regarding the management
recommendations (Dekanek et al., 2019). In fact, in a study of 86 OB/GYN and family
practice physicians, only 44% of participants felt somewhat confident in discussing
BRCA management guidelines, and none of the participants indicated that they felt
completely confident (Dekanek et al., 2019).
Other studies have looked at patients’ perceived barriers to getting appropriate
cancer management. These studies have found that scheduling difficulties are a factor
preventing proper adherence to management (Goh & Spigelman, 2020; Young et al.,
2019). In addition, confusion surrounding insurance coverage for screening has also been
found to be a barrier to accessing these services (Dean et al., 2017). Previvors are in need
of healthcare providers who are not only knowledgeable of the management guidelines,
but also how to follow through with scheduling and the logistics of following those
guidelines.
Although the services included in a previvor clinic will likely vary between
clinics, several needs among previvors remain the same. First, because scheduling
screenings and appointments is a frequent challenge among previvors, a primary role of
this clinic should be to establish a clear appointment plan for patients. A study by Young
et al. (2019) of the information needs of previvors found that previvors wanted genetics
providers to make referrals to other specialists, such as psychologists, surgeons, or other
specialists. Generally, genetic counselors make the initial recommendations for the
patient, but rely on the referring provider to make the necessary referrals, potentially
causing interruptions in the patient’s transition of care. This is largely due to the scope of
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practice defined by the National Society of Genetic Counselors, which states that genetic
counselors have the authority to:
“Identify, order, and coordinate genetic laboratory tests and other diagnostic
studies as appropriate for the genetic assessment; integrate genetic laboratory test
results and other diagnostic studies with personal and family medical history to
assess and communicate risk factors for genetic/medical conditions and diseases;
and identify and utilize community resources that provide medical, educational,
financial, and psychosocial support and advocacy” (National Society of Genetic
Counselors, 2021).
Because under the society’s scope of practice genetic counselors are unable to refer to
outside physicians, this responsibility is placed on either the referring provider or the
patient to get connected with these medical specialists.
One potential model for a previvor clinic has been created by the Stefanie
Spielman Comprehensive Breast Center in Columbus, Ohio (Senter & Hatfield, 2016).
This clinic has high-risk breast cancer patients meet with a cancer genetic counselor first
to take a family history and make genetic testing recommendations if warranted.
Following the genetic consultation, the patient meets with a nurse practitioner specialized
in breast health or a breast, surgical, or medical oncologist who assists in making
management recommendations. Many patients receive high-risk breast cancer screening
including mammograms, breast MRIs, and clinical evaluation. The clinic model staggers
these appointments by six months and alternates visits between the physician and the
nurse practitioner. An updated family history is taken at each visit and the cancer genetic
counselor may return to see the patient to discuss additional recommendations. Genetic
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counselors also serve as a resource for questions regarding genetic testing for family
members or other genetics-related considerations. (Senter & Hatfield, 2016). This model
addresses the complications of scheduling follow-up appointments for recommended
management.
Although many genetic counselors may be unable to serve as full-time staff of a
previvor clinic, they play an important role in the care of previvors and should be closely
integrated with a specialty clinic. The exact role of the genetic counselor would likely
depend on the overall clinic setup as well as the needs of the individual patient. For
example, a genetic counseling consult may be requested when a patient is considering
family planning decisions, when family history has changed significantly, or when
updates to genetic testing have been made. The primary medical staff for a previvor clinic
would likely consist of a nurse practitioner and/or physician. The nurse practitioner
and/or physician can provide initial screening services and make referrals to necessary
specialists including, but not limited to, oncology, plastic surgery, nutritional services,
psychological services, and reproductive endocrinology. The establishment of a
specialized previvor clinic would allow for unhindered access to resources and support in
cancer prevention and management, which has potential to improve outcomes for these
individuals (Senter & Hatfield, 2016).
1.9 Rationale of Study
Although there is research into the unique needs of previvors and individuals at an
increased risk for cancer, there is little information about previvors’ opinions on the
establishment of a management clinic in general, and nothing specific for the state of
South Carolina. The goal of this study is to determine if patients in Columbia, South
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Carolina would benefit from the establishment of a specialized management clinic, and if
so, what services these individuals need. It is our belief that this study will bring no harm
to the participant but will provide valuable insight into how to best care for this patient
population. We will also pull from experiences from a currently established clinic in
South Carolina to gather opinions on an already available service.
1.10 Objectives
1. Determine if there is desire and/or need for a previvor clinic in Columbia, South
Carolina
2. Determine the utility and efficacy of the Genetics Management Clinic and HighRisk Breast Lifetime Clinic in Greenville, South Carolina
3. Determine what services should be incorporated into such a clinic and how often
patients would require these services
4. Assess whether patients who had access to a previvor clinic were better able to
adhere to management recommendations compared to those who did not have
access
1.11 Hypothesis
It is hypothesized that without clear direction and guidance from knowledgeable
health professionals, many previvors may struggle to adhere to NCCN management
guidelines. Without proper care, previvors are at risk for worsened health outcomes, so it
is expected that this study may improve overall patient satisfaction and care.
Furthermore, it is anticipated that patients within the Columbia, South Carolina area will
have strong interest for the establishment of a local previvor clinic and that patients who
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have attended the specialty clinic in Greenville will experience high patient satisfaction
and will attest to the value and benefit of such a clinic.
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CHAPTER 2: PREVIVOR AND HIGH-RISK BREAST CANCER PATIENTS’
OPINIONS ON A SPECIALIZED MANAGEMENT CLINIC1

1

Tjoelker, M., Dobek, W., Perkins, L., Stapleton, G., & Kim, J. To be submitted to the
Journal of the Advanced Practitioner in Oncology
17

2.1 Abstract
Approximately 5-10% of cancers are thought to be hereditary, caused by
pathogenic variants in genes associated with inherited cancer syndromes. Previvors,
individuals who have a higher predisposition to cancer due to genetic or other risk
factors, have specific healthcare and psychological needs that may be better served by a
specialized management clinic. This study compared the experiences of previvors who
had access to a specialized management clinic with those who did not, in order to better
understand the unique needs of previvors. This study utilized a mixed methods design
including an online survey (N=26) and semi-structured phone interview (N=6). Overall,
previvors with access to a specialized management expressed less stress (N=5), less delay
in care (N=2), access to a simplified clinical process (N=5), and the information needed
to make informed decisions regarding their medical care (N=8). Previvors who did not
have access to a specialty clinic described challenges with finding information about their
risk, receiving care from general practitioners, and having questions unanswered by
healthcare providers, further supporting previous literature that investigated the nuanced
care required by previvors. Previvors without access to a management clinic desired a
team of specialists familiar with genetics, a forum to ask questions, and a clinic that
would ensure their care meets the current recommendations. This study demonstrates the
need for specialized management clinics designed with previvors’ needs in mind in order
to provide these patients with the most appropriate care.
2.2 Introduction
Approximately 5-10% of cancers are thought to be hereditary. Hereditary cancer
is caused by mutations in genes associated with hereditary cancer syndromes, and a
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pathogenic mutation results in a significantly increased risk for cancer development
compared to that of the average population (Senter & Hatfield, 2016). Mutations that
cause hereditary cancer syndromes are identified through the use of genetic testing,
specifically testing that targets oncogenes and tumor suppressor genes, genes associated
with regulation of cell growth and hereditary cancer (Dekanek et al., 2019). Once a
pathogenic mutation has been identified, it is recommended that the patient pursue
management specific to their cancer risks, often as directed by the guidelines established
by the National Comprehensive Cancer Network (NCCN), a society recognized in the
medical community to be an authority on cancer care (NCCN, 2020).
There are a large number of genes associated with hereditary cancer. This study
encompassed individuals with mutations in ATM, BRCA1, BRCA2, CDH1, CHEK2,
PALB2, PTEN, and TP53. While these genes are mainly associated with breast cancer,
mutations in them also carry other cancer risks. In addition, these genes have specific
management recommendations established by NCCN that aid in patient care (NCCN,
2020).
Genetic testing for hereditary cancer syndromes is recommended for individuals
who meet certain criteria as determined by NCCN. One example of this criteria is the
Testing Criteria for High-Penetrance Breast and/or Ovarian Cancer Susceptibility Genes,
determined by NCCN (NCCN, 2020). If criteria are met, and no familial mutation has
been identified, providers should consider comprehensive testing for the patient with a
multi-gene panel (NCCN, 2020). NCCN (2020) recommends genetic testing for
hereditary breast and ovarian cancer for patients with certain cancer diagnoses or if a
family history meets certain criteria.
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By pursuing testing for a known familial variant or because of a family history of
cancer, individuals are learning of their previvor status. The term previvor was initially
coined by the advocacy group, Facing Our Risk of Cancer Empowered (FORCE), and is
used to describe individuals “who have a much greater predisposition to cancer than
individuals in the general population but who have not yet developed the disease”
(Carvalho et al., 2019, p. 1). This greater susceptibility may be due to the presence of a
pathogenic mutation in a hereditary cancer gene or other factors including family history
(Getachew-Smith et al., 2019). It has been recognized that individuals falling within the
previvor category have “specific psychosocial and healthcare needs…to help them decide
how to manage this substantial risk” (Mahon, 2014, p. 21).
Individuals with mutations in hereditary cancer genes have specific management
recommendations established by the National Comprehensive Cancer Network, but
recommendations differ slightly from gene to gene. Individuals who fall into the previvor
category based on family history or other factors can be identified using verified risk
models, such as Tyrer-Cuzick, Gail, BRCAPRO, Claus, and BOADICEA. Women with a
lifetime risk of breast cancer greater than or equal to 20% as determined by these models
are recommended to have additional screening similar to that recommended for
individuals with a genetic mutation (Monticciolo et al., 2018). Recommendations include
breast awareness, clinical breast exams every six to twelve months, annual breast MRI
beginning at age 25, annual mammogram beginning at age 30, and incorporation of riskreducing strategies, such as the use of tamoxifen as a form of chemoprevention (NCCN,
2020). Because cancer risks vary from gene to gene, it is important to know the patient’s
carrier status when determining a management plan.
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There is little data on how previvors are conducting cancer screening and
management or how closely they are following the NCCN screening guidelines.
However, in a study by Hesse-Biber and An (2016), researchers looked at surgical
decision-making among BRCA-positive individuals. The main factors that went into
surgical decision-making included age, parental status, gender of the children, level of
psychological distress from the BRCA result, perceived family support, experienced
medical uncertainty, and the level of guilt they felt about passing the mutation to their
children. Women who experienced more distress related to their BRCA result, those who
felt they lacked support from their family, and those who perceived more medical
uncertainty were more likely to choose surveillance rather than surgery (Hesse-Biber &
An, 2016). Another study, by Hoskins, Roy, and Greene (2012), analyzed patients’ risk
perception of their BRCA1 or BRCA2 mutation. In their study of 60 participants, 17 had
already undergone a prophylactic mastectomy and eight had completed an oophorectomy.
An additional 34 participants were either considering or concretely planning a riskreducing mastectomy and 45 were either considering or concretely planning a
prophylactic oophorectomy. The authors concluded that many previvors may initially
choose to manage with increased surveillance before electing to proceed with
prophylactic surgery (Hoskins et al., 2012). Neither study explored previvors’ adherence
to management recommendations if proceeding with screening surveillance, suggesting
that further research in this area is needed.
Individuals with a predisposition to cancer have unique needs compared to the
average population. In a study by Dean and Davidson (2018), it was found that these
individuals may have increased levels of uncertainty compared to those at average risk
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for cancer. In fact, researchers found that previvors experience high levels of uncertainty,
and increased uncertainty can result in “emotional distress, anxiety, depression, loss of
control, and poor decision making and quality of life” (p. 122). In order to manage this
uncertainty, previvors make decisions based on their perceived risk and available
information, so it is imperative that these individuals are receiving accurate information
and support (Dean & Davidson, 2018). Furthermore, Mahon (2014) found that, although
some online organizations and support groups are available, many of these individuals
feel isolated, labeled, or feel different from others without a mutation.
Previvors have described their experience with their healthcare providers as
overwhelming and exhausting because they have been tasked with teaching their
providers about their risk and management instead of receiving the empathy and
psychosocial support they need (Dean & Davidson, 2018). These individuals are even
faced with opposition to their decision to select risk-reducing surgery to reduce cancer
risk, by claims that prophylactic surgery is too extreme. And even if supported in their
decision to pursue prophylactic surgery, these individuals face unique challenges as a
result of their surgery. Some women, after a risk-reducing mastectomy, have self-image
difficulties and lack of security in their identity (Mahon, 2014). After a risk-reducing
salpingo-oophorectomy, women may experience altered self-image, increased depression,
increased fatigue, sleep deprivation, and sexual dysfunction that can change her desire for
intimacy and ultimately affect personal relationships (Alexandre et al., 2017).
Although much of a previvor’s uncertainty may arise from the potential to
develop cancer, previvors are also concerned about the impact their risk has on other
family members. In a study assessing perspectives of young adults at risk to have a
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BRCA mutation, many participants emphasized the need for information about
reproductive issues and family planning (Young et al., 2019). Individuals who carry a
genetic mutation are at risk of their children inheriting this mutation and also have to
weigh the option of breastfeeding their child or reducing their cancer risk with riskreducing mastectomy. In addition, previvors may be worried about the risk to their
children and when to communicate about that risk (Mahon, 2014).
These unique needs of previvors and high-risk breast cancer patients support the
necessity of a specialty clinic for previvor management. As described above,
management for previvors and high-risk breast cancer patients is complex and variable,
thus it is imperative that individuals are managed by healthcare professionals who are
knowledgeable about the personalized care required. Studies have shown that obstetrics
and gynecology (OB/GYN) providers and family practice providers are not able to give
previvors optimal care, primarily due to a lack of confidence regarding the management
recommendations (Dekanek et al., 2019). In fact, in a study of 86 OB/GYN and family
practice physicians, only 44% of participants felt somewhat confident in discussing
BRCA management guidelines, and none of the participants indicated that they felt
completely confident (Dekanek et al., 2019).
Other studies have looked at patients’ perceived barriers to getting appropriate
cancer management. These studies have found that scheduling difficulties are a factor
preventing proper adherence to management (Goh & Spigelman, 2020; Young et al.,
2019). In addition, confusion surrounding insurance coverage for screening has been
found to be a barrier to accessing these services (Dean et al., 2017). Previvors are in need
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of healthcare providers who are not only knowledgeable of what the guidelines are, but
also how to follow through with scheduling and logistics of following those guidelines.
Although the services included in a previvor clinic will likely vary from clinic to
clinic, several needs among previvors remain the same. First, because scheduling
screenings and appointments is a frequent challenge among previvors, a primary role of
this clinic should be to establish a clear appointment plan for patients. A study by Young
et al. (2019) of the information needs of previvors found that previvors wanted genetics
providers to make referrals to other specialists, such as psychologists, surgeons, or other
specialists. Generally, genetic counselors make the initial recommendations for the
patient, but rely on the referring provider to make the necessary referrals, potentially
causing interruptions in the patient’s transition of care.
One potential model for a previvor clinic has been created by the Stefanie
Spielman Comprehensive Breast Center in Columbus, Ohio (Senter & Hatfield, 2016).
This clinic has high-risk breast cancer patients meet with a cancer genetic counselor first
to take a family history and make any genetic testing recommendations if warranted.
Following the genetic consultation, the patient meets with a nurse practitioner specialized
in breast health or a breast, surgical, or medical oncologist who assist in making
management recommendations. Many patients receive high-risk breast cancer screening
including mammograms, breast MRIs, and clinical evaluation. The clinic model staggers
these appointments by six months and alternates visits between the physician and the
nurse practitioner. An updated family history is taken at each visit and the cancer genetic
counselor may return to see the patient to discuss additional recommendations. Genetic
counselors also serve as a resource for questions regarding genetic testing for family
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members or other genetics-related considerations (Senter & Hatfield, 2016). The model
addresses the issues of scheduling follow-up appointments for management. Clinic
organization will vary, as will the role of the genetic counselor’s involvement, but
patients need access to a provider who can refer to specialists and establish support
resources, and a similar model to the one described above would be of great benefit to the
patients of Columbia, South Carolina.
The goal of this study was to determine if there was a desire and/or need for a
previvor clinic in Columbia, South Carolina and to determine the utility and efficacy of
the existing clinics in Greenville, South Carolina—the Genetics Management Clinic and
High-Risk Breast Lifetime Clinic. In addition, researchers sought to determine what
services ought to be incorporated into such a clinic and how often patients would require
these services. Lastly, by comparing experiences of individuals at both hospitals,
researchers hoped to assess whether patients who had access to a previvor clinic were
better able to adhere to management recommendations compared to those who did not
have access. It was hypothesized that, without clear direction and guidance from
knowledgeable health professionals, many previvors may struggle to adhere to NCCN
management guidelines. Without proper care, previvors are at risk for worsened health
outcomes, so it is expected that this study may improve overall patient satisfaction and
care. Furthermore, it was anticipated that patients within the Columbia, South Carolina
area would have strong interest for the establishment of a local previvor clinic and that
patients who have attended the specialty clinic in Greenville experienced high patient
satisfaction and will attest to the value and benefit of such a clinic.
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2.3 Methods
2.3.1 IRB Approval
This study was approved by the Institutional Review Board, Office of Research
Compliance, of the University of South Carolina, Columbia, SC in July 2020.
2.3.2 Participants
Participants included in this study were patients who had a genetic counseling
appointment at Prisma Health-Midlands in Columbia, South Carolina or an appointment
at the Genetics Management Clinic or High-Risk Breast Lifetime Clinic at Prisma Health
Upstate in Greenville, South Carolina. To be included in the study, patients were required
to meet the following inclusion criteria: Mutation-positive in a hereditary cancer gene
that predisposes to breast cancer and has NCCN management recommendations,
including: ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, TP53, or have a
Tyrer-Cuzick or other risk model score of 20% or greater, requiring additional
management as dictated by the NCCN Genetic/Familial High-Risk Assessment: Breast,
Ovarian and Pancreatic guidelines; and never had a diagnosis of cancer (NCCN, 2020).
Prisma Health-Midlands patients who are mutation-positive were recruited
retroactively through the clinic’s database and prospectively as encountered by the
Prisma Health-Midlands genetic counselors. Prisma Health-Midlands patients who are
considered high-risk given their Tyrer-Cuzick score were informed of the study
prospectively by their genetic counselor. Prisma Health-Upstate patients who have visited
the Genetics Management Clinic or High-Risk Breast Lifetime Clinic and met the
inclusion criteria were identified through the clinic’s records and sent a recruitment letter
inviting them to participate in the study.
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2.3.3 Online Survey
Participants were mailed a letter inviting them to complete an online survey
through QualtricsXM software. Invitation letters were mailed out to patients of the
Genetics Management Clinic and High-Risk Breast Lifetime Clinic in August 2020.
Additionally, Prisma Health-Midlands patients who received genetic counseling in the
past and were mutation-positive also were sent an invitation letter at this time. Beginning
in August 2020, Prisma Health-Midlands patients who received negative genetic testing
but were identified to be high risk for breast cancer were given a letter by their genetic
counselor, inviting them to participate in the study. Included in the recruitment letter was
a link to the participant’s clinic-specific survey (Appendix A-C). The survey remained
open until November 15, 2020. At the beginning of the survey, participants were asked to
provide informed consent by selecting the “I consent” option. Data collection was kept
anonymous to protect the privacy of the participants.
Surveys were unique to the clinic the participants were involved with and
included a mixture of questions addressing patient demographic information, genetic
status, clinic satisfaction, and further suggestions for clinic development and
improvement (Appendix D-F). The final question of all three surveys invited participants
to list their phone number if interested in participating in a semi-structured phone
interview. By providing their phone number, participants consented to being contacted by
the principal investigator for this purpose.
2.3.4 Semi-Structured Interviews
Participants who indicated on the survey their willingness to partake in an
additional interview were called to complete a semi-structured phone interview regarding
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their experiences at their respective clinic (i.e., Prisma Health-Midlands Genetic
Counseling, Genetics Management Clinic, or High-Risk Breast Lifetime Clinic). Prior to
beginning the interview, participants were asked to give verbal consent to participate in
the interview and have their responses recorded. Surveys were transcribed by hand,
labeled numerically by the order in which they were completed, and secured on a
password-protected computer.
2.3.5 Data Analysis
All data remained deidentified to protect the privacy of the participants. Survey
responses to multiple choice questions and ranking activities were analyzed and
frequencies were recorded for analysis. Free response questions and qualitative
interviews were analyzed for themes using a grounded theory approach, and shared
themes were drawn from both the surveys and interviews. This analysis was completed
by two independent researchers (M.T. and W.D.), and categories were discussed until
three common themes were agreed upon.
2.4 Results
2.4.1 Participation and Demographics
A total of 28 surveys were started, and 26 were completed across the three clinics.
Seven surveys were completed by Prisma Health-Midlands patients, ten by Genetics
Management Clinic patients, and nine by High-Risk Breast Lifetime Clinic patients. Six
semi-structured phone interviews were completed—four by Prisma Health-Midlands
patients and two by Genetics Management Clinic patients. An additional eight
participants indicated on their survey that they would be willing to complete a semistructured phone interview but were unable to be contacted to arrange the interviews.
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Table 2.1 Demographic Characteristics of Participants
Characteristic
N (Percentage)
Clinic
Prisma Health-Midlands
7 (26.9%)
High-Risk Breast Lifetime Clinic
10 (38.5%)
Genetics Management Clinic
9 (34.6%)
Age (Obtained for Prisma Health-Midlands Only)
18-25
1 (14.3%)
26-30
1 (14.3%)
31-40
1 (14.3%)
41-50
0 (0%)
51-60
2 (28.6%)
61-70
1 (14.3%)
Over 70
1 (14.3%)
Genetic Status
Positive
16 (61.5%)
Negative/High-Risk
10 (38.5 %)
Gender*
Female
26 (100%)
Male
0 (0%)
*Both men and women were eligible for the study, however, all participants reported
female gender identity.
2.4.2 Prisma Health-Midlands
A total of nine surveys were started, and seven surveys were completed. Of the
seven completed surveys, six participants indicated they had a mutation in a hereditary
cancer gene, while the remaining participant had a high lifetime risk for breast cancer
based on her family history. Figure 2.1 shows the risk status of Prisma Health-Midlands
participants, including genes in which participants had a pathogenic variant and those
who tested negative and are high risk based on other factors.

29

Prisma Health-Midlands Risk Status
Negative
14%
PALB2
14%
CHEK2
14%

BRCA1

BRCA2

BRCA1
29%

BRCA2
29%

CHEK2

PALB2

Negative High-Risk

Figure 2.1 Prisma Health-Midlands Risk Status
One participant had a history of cancer, and as a result, the survey was ended after
answering that she had a cancer diagnosis. Therefore, the total number of complete,
eligible responses for the Prisma Health-Midlands clinic was six surveys.
Participants were asked to rate their attitudes regarding their risk perception and
care they currently receive related to their cancer predisposition. These attitudes are
summarized in Table 2.2.
Table 2.2 Patient Attitudes Regarding Cancer Risk and Care
Patient Attitudes
N (Frequency)
I feel I have adequate knowledge about my cancer risk and am able to manage my
personal healthcare to meet the recommendations.
Strongly agree
1 (16.7%)
Somewhat agree
3 (50%)
Neither agree nor disagree
2 (33.3%)
Somewhat disagree
0 (0%)
Strongly disagree
0 (0%)
I feel that my healthcare providers (primary care physician, obstetrician, gynecologist,
etc.) have expert knowledge about the cancer screenings recommended for me.
Strongly agree
0 (0%)
Somewhat agree
2 (33.3%)
Neither agree nor disagree
2 (33.3%)
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Somewhat disagree
1 (16.7%)
Strongly disagree
1 (16.7%)
I have difficulty getting insurance coverage for the recommended cancer screenings.
Strongly agree
1 (16.7%)
Somewhat agree
0 (0%)
Neither agree nor disagree
3 (50%)
Somewhat disagree
1 (16.7%)
Strongly disagree
1 (16.7%)
Some institutions have set up clinics designed to assist individuals who carry a positive
mutation in a hereditary cancer gene or who are at a higher risk for developing breast
cancer get the recommended screenings and management. How interested would you
be in attending this clinic if it were created at Prisma Health-Midlands?
Very interested
6 (100%)
Somewhat interested
0 (0%)
Neutral
0 (0%)
Likely not interested
0 (0%)
Not at all interested
0 (0%)
How often would you want to attend this type of clinic? (If other, please specify in the
provided blank.)
Only once
1 (16.7%)
Every 5 years
0 (0%)
Every 2 years
0 (0%)
Every year
1 (16.7%)
Every 6 months
2 (33.3%)
Other— “As often as recommended”
1 (16.7%)
Other— “Every 3 months”
1 (16.7%)
The majority of participants reported feeling very confident or somewhat
confident that they had adequate knowledge of their cancer risks and had the ability to
manage their healthcare accordingly (N=4, 66.7%). However, when asked the degree to
which they agree that their healthcare providers had expert knowledge of their cancer risk
and the recommended screenings, no participants strongly agreed. One-third (33.3%,
N=2) somewhat felt that their providers had expert knowledge regarding their risks and
management, and one-third (33.3%, N=2) of participants did not feel they had this
knowledge.
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All six participants (100%) indicated that they were very interested in attending a
specialized management clinic if one were developed at Prisma Health-Midlands.
Participants were then given a list of possible services and asked to rank these services in
order of most important to least important for incorporation into a specialized
management clinic. Services were ranked by each participant and weighted frequencies
were calculated for each category based on participant responses (Appendix G). The
results of this ranking question are summarized in Figure 2.2.

Ranked Preferences of Services Prisma Health-Midlands
40

Weighted Frequency

35
30
25
20
15
10
5
0
Cancer
Screenings

Psychological
Support

Genetic
Counseling

Nutritional
Services

Oncology

Plastic Surgery

Service

Figure 2.2 Ranked Preferences of Services—Prisma Health-Midlands
The majority of participants ranked access to cancer screenings (i.e., mammogram, breast
MRI, etc.) as most important, while psychological support was ranked overall as least
important.
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2.4.3 Genetics Management Clinic
A total of ten surveys were completed by patients of the Genetics Management
Clinic; however, only four of the participants met all of the inclusion criteria for the
study. Due to the limited number of responses, answers from participants who completed
the survey but had a personal history of cancer were still included.
Participants identified as having pathogenic variants in three hereditary cancer
genes: BRCA1, BRCA2, and PALB2, with the majority of participants (N=5, 50%)
carrying a BRCA2 variant. Figure 2.3 shows the breakdown of genetic mutation status by
gene.

Genetics Management Clinic - Genetic
Mutation Status
PALB2
10%
BRCA1
40%
BRCA2
50%

BRCA1

BRCA2

PALB2

Figure 2.3 Genetics Management Clinic Genetic Mutation Status
After learning of their genetic status, the majority of participants (N=8, 80%)
have attended the Genetics Management Clinic for longer than 18 months. On average,
most participants attended the clinic once per year and felt that this interval between
visits was appropriate (N=9, 90%). When asked to rate their satisfaction with the clinic on
a scale from one to ten (1 being not at all satisfied and 10 being very satisfied), 90%
33

(N=9) rated their satisfaction with the clinic a 10, very satisfied. Additionally, all ten
participants indicated that they would recommend the GMC to others (100%).
2.4.4 High-Risk Breast Lifetime Clinic
A total of nine surveys were completed by participants of the High-Risk Breast
Lifetime Clinic. 88.9% of participants (N=8) have attended the High-Risk Breast
Lifetime Clinic for at least 12 months. Four participants indicated that they visit the
High-Risk Breast Lifetime Clinic semi-annually (50%), three participants attend annually
(37.5%), and one participant no longer attends the clinic (12.5%). Overall, participants
expressed high satisfaction with the care they received at the High-Risk Breast Lifetime
Clinic as seen in Table 2.3, with all participants ranking their satisfaction greater than or
equal to seven on a number scale identifying satisfaction, and the majority (55.5%, N=5)
ranking satisfaction greater than or equal to nine. Two-thirds (66.7%, N=6) expressed
that breast cancer screenings had gotten easier since attending the High-Risk Breast
Lifetime Clinic.
Table 2.3 High-Risk Breast Lifetime Clinic Patient Satisfaction and Clinic Utility
High-Risk Breast Lifetime Clinic Patient Satisfaction
and Clinic Utility
N (Frequency)
On a scale from 0-10, with 0 being not at all satisfied and 10 being very
satisfied, how satisfied are you with the services provided by the HighRisk Breast Lifetime Clinic?
0- not at all satisfied
0 (0%)
1
0 (0%)
2
0 (0%)
3
0 (0%)
4
0 (0%)
5
0 (0%)
6
0 (0%)
7
2 (22.2%)
8
2 (22.2%)
9
2 (22.2%)
10- very satisfied
3 (33.3%)
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Has getting breast cancer screening (i.e., mammograms and breast MRIs)
gotten easier since attending this clinic?
Yes
No
Not sure

6 (66.7%)
2 (22.2%
1 (11.1%)

2.4.5 Experiences with Genetic Counseling
All participants were able to meet with a genetic counselor either prior to or
following genetic testing. Participants expressed high levels of satisfaction with their
genetic counseling experience, especially in terms of level of thoroughness and education
they received regarding their cancer risk. Participants appreciated the expert genetic
knowledge of genetic counselors coupled with their attention to psychosocial concerns of
the patient and their relatives. Participants described the process of meeting with a
genetic counselor to discuss genetic test results, associated risks, and options for future
care. One participant compared her experience seeing a genetic counselor at Prisma
Health-Midlands to her sister’s experience at her doctor’s office:
Well, I was so pleased with the whole experience with the genetic counseling…
And when I compare my experience to my sister who just had a blood test at her
OB/GYN and just sent a letter in the mail, she really had no counseling. She filled
out a family history, but nobody questioned or interviewed her or anything.
Totally different experience. And she was so jealous when I told her my
experience and what I went through and how supportive everybody was. (Prisma
Health-Midlands Participant 7)
As described by Prisma Health-Midlands Participant 7 and several others, benefits of
genetic counseling included psychosocial support, thorough education regarding cancer
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risks, and discussion of options to reduce cancer risk (Prisma Health-Midlands
Participant 7, Genetics Management Clinic Participant 4 & 5).
2.4.6 Experiences of Participants Without a Specialized Clinic
Without access to a specialized management clinic, participants rely on online
support groups, current medical providers, and self-advocacy to get care related to their
cancer predisposition. After learning of her CHEK2 mutation, Prisma Health-Midlands
Participant 1 relied on a Facebook group for CHEK2 mutation carriers to keep her up to
date. Members of the Facebook group willingly shared their experiences and research on
CHEK2 variants, but this led to additional questions about associated cancer risks and
management options. Prisma Health-Midlands Participant 1 described the dynamic of this
group as a “big question and a big waiting game,” when expressing the confusion that can
surround online support groups. Despite some confusion regarding cancer risks, Prisma
Health-Midlands Participant 1 pointed out that a major benefit of the online support
group was the allied search for information. She described that the members of the group
actively search out research regarding CHEK2 and willingly share it with the group,
although she recognized that information is somewhat limited.
Other participants relied on support from their family members who also carry the
same variant. Prisma Health-Midlands Participant 4 described talking with her mother
about their risks for breast cancer: She recalled talking with her mother about the
different options for risk-reduction but concluded that they would address cancer or
management if it came to fruition.
Previvors without a specialized management clinic relied on the experience of
their current medical provider (primary care physician, OB/GYN, etc.) for care related to
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their increased risk for breast and other cancers. Some participants expressed high levels
of satisfaction with their current provider’s knowledge regarding their cancer
predisposition, while others felt that they had to educate their providers about their
increased risk and recommended risk-reduction options. Prisma Health-Midlands
Participant 1 described her visits with her nurse practitioner after learning of her positive
CHEK2 variant and explained that her nurse practitioner had been helpful in arranging
the necessary screenings. Together, they looked at her genetic testing results and
recommendations for management and came up with a plan of action, including
scheduling a mammogram and breast MRI. Prisma Health-Midlands Participant 1 also
planned to discuss scheduling a colonoscopy in the near future and believed that her
nurse practitioner would be able to help facilitate that referral.
Although Prisma Health-Midlands Participant 1 felt that her provider was wellequipped to care for her, not all participants felt the same regarding their providers.
Prisma Health-Midlands Participant 3 found that some of her providers did not fully
understand her cancer predisposition or the recommendations for screenings or riskreducing care:
It’s hard to like to tell a doctor like, “hey, I need this done or this done,” you
know, like when… it’s hard to speak up and say that when they know so much
more about medical things than you do. (Prisma Health-Midlands Participant 3)
Prisma Health-Midlands Participant 7 described a similar situation in which a provider
could not comprehend her desire to reduce her breast cancer risk in any way possible:
Because after watching family members go through this, I have even asked my
doctor—before we even talked about the genetic counseling—I asked her about
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the possibility of having my breasts removed. And she looked at me like, “What?”
And I’m like, “Well, you know, that would just kind of eliminate that…” I’m
open to anything. Whatever I can do to not have to go through what I’ve watched
other family members go through. (Prisma Health-Midlands Participant 7)
Like Prisma Health-Midlands Participants 3 and 7 described, previvors without a
specialized clinic felt they needed to self-advocate for their desire to be proactive to
healthcare providers who did not understand their risk, but previvors also found they had
to do so with family members who did not understand their desire to reduce cancer risk in
any way possible. Prisma Health-Midlands Participant 1 described a conversation with
her husband regarding genetic testing and risk reduction in which he described genetic
testing as “fearmongering,” but she defended her position on testing and risk-reduction
because of experiencing the loss of a close friend at age 29 due to breast cancer, claiming
that she would do anything she could to be prepared. These encounters with people who
do not understand their predisposition, have sparked participants to do everything in their
own power to prevent cancer.
When asked what features participants would include in an ideal management
clinic, participants highlighted the need for access to specialists familiar with genetics, a
provider who will notify of changes to risk or management recommendations, and a place
to ask questions. Participants desired a specialist familiar with genetics and able to
provide expert care specific to their risks, whether due to a genetic mutation or family
history. Prisma Health-Midlands Participant 4 described how the providers at a local
women’s center performed her breast ultrasound and were familiar with breast health but
did not have expert knowledge on the genetic aspects of her care. After leaving her visit
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at the women’s center, she felt that there were still probably things related to her risk that
she didn’t know about. She emphasized the difference between a women’s center who
specializes in women’s care and breast cancer screening versus a center that focuses on
this care and screening within the context of previvorship. Prisma Health-Midlands
Participant 3 echoed this sentiment, saying that she simply wanted a place where the
doctors were familiar with the higher risks of previvors.
A second priority for a specialized management clinic was the ability to be
notified of changes to cancer risks or management recommendations. Prisma HealthMidlands Participant 4 indicated that this would be a priority for her when thinking about
a specialized clinic and emphasized her desire for a healthcare provider that could follow
her along and provide updates on changes to care. Similarly, Prisma Health-Midlands
Participant 1 valued the idea of having a specific provider to keep patients informed, to
help patients stay informed and on top of their care in addition to providing resources.
She also emphasized the importance of having new information explained by a medical
professional in layman’s terms, ensuring their ability to utilize that information.
In addition to using the clinic as a way to stay informed, participants also wanted
the clinic to serve as the place to ask questions and get specific recommendations based
on their genetic mutation or family history. Prisma Health-Midlands Participant 1
described the confusion that has come up in her CHEK2 Facebook group regarding
associated cancers and risks and described that a specialized management clinic with
specific knowledge regarding care for individuals with a CHEK2 mutation would be
extremely beneficial in order to get her questions answered. Prisma Health-Midlands
Participant 4 expressed interest in asking questions about risk-reducing surgeries and
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other screening options and felt that there was probably information about these options
that she was unfamiliar with. Similarly, Prisma Health-Midlands Participant 7 discussed a
conversation with her sister about taking tamoxifen and how she was not certain that
taking it was still recommended. She also had questions regarding the benefits of a breast
MRI and the logistics of getting one.
2.4.7 Experiences of Participants with a Specialized Clinic
Participants from the Genetics Management Clinic and High-Risk Breast Lifetime
Clinic expressed that access to a specialized management clinic provided a simplified and
efficient management process, streamlining their care. Genetics Management Clinic
Participant 4 described the role of the nurse practitioner who heads the clinic as a
navigator and facilitator. The nurse practitioner would provide referrals to the necessary
specialists, assist in scheduling appointments for consults and imaging, and provided
insight on proper care and management. By navigating the process alongside the patient,
the nurse practitioner was able to expedite care and ensure the patient received the
appropriate services, removing the burden from the patient. High-Risk Breast Lifetime
Clinic Participant 7 echoed this feeling, stating that the High-Risk Breast Lifetime Clinic
providers had an expert focus on identifying, treating, and curing breast disease, which
she found particularly helpful. High-Risk Breast Lifetime Clinic Participant 8 expressed
that the ease of visits and concentration on breast cancer risk-reduction and care were the
most valuable aspects of the clinic.
In addition to providing care in a simplified manner, participants expressed that
this system also prevented delays to care. Genetics Management Clinic Participant 7
mentioned that she was able to get a second surgery quicker because of having access to
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the physicians at the Genetics Management Clinic. Genetics Management Clinic
Participant 4 discussed how she might have approached clinical care after learning of her
BRCA1 mutation, and how the clinic’s approach ensured she saw the proper physicians
quickly. Instead of seeing one doctor at a time and approaching care in a step-wise
fashion, the clinic made the referrals simultaneously. Having access to a specialized
management clinic allowed her care to be expedited compared to if she had coordinated
her care plan own her own. She believed that she would’ve seen all of the recommended
physicians eventually, but never would have done so at such a high speed if it had not
been for the Genetics Management Clinic.
Study participants emphasized that a major benefit of the Genetics Management
Clinic and High-Risk Breast Lifetime Clinic is access to healthcare providers who give
detailed education regarding risk and the necessary information to come to an informed
decision regarding care and risk-reduction. Genetics Management Clinic Participant 8
described genetic counseling as the most valuable service of the Genetics Management
Clinic and how after discussing her mutation in-depth, she felt much better about her plan
for care. Genetics Management Clinic Participant 5 expressed similar feelings and
explained how receiving thorough education about her genetic mutation and what it
meant allowed her to not only be proactive but gave her a sense of control. By receiving
proper education about their elevated risk for developing cancer, participants were able to
make educated, well-informed decisions relating to their care plan, whether electing to
proceed with screening or a risk-reducing surgery.
Furthermore, access to the Genetics Management Clinic or High-Risk Breast
Lifetime Clinic reduced participant stress related to receiving care. Several participants
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described the sense of relief they experienced after connecting with the clinic. Genetics
Management Clinic Participant 5 highlighted this feeling when describing how the clinic
recommended where to go, which providers to see, and facilitating scheduling. By
leaving this in the hands of the Genetics Management Clinic, she was able to feel more
relaxed and less overwhelmed by the process. High-Risk Breast Lifetime Clinic
Participant 5 shared that she found “peace of mind knowing the High-Risk Breast
Lifetime Clinic is closely monitoring everything.” Numerous participants expressed that
the process of learning of their increased risk and determining a management plan could
be overwhelming, but the clinics help make it manageable (Genetics Management Clinic
Participant 5). Genetics Management Clinic Participant 4 describes the overall impact the
Genetics Management Clinic had on her, saying:
I would just say that they're useful. I mean, if it wasn’t for the clinic, could I have
done all this? Yes, but with them doing it, it was more efficient, it was less
stressful for me, it was one less thing I had to research. It just made the whole
process just a little bit easier—a lot easier, not a little, a lot. I only have positive
things to say. (Genetics Management Clinic Participant 4)
2.5 Discussion
2.5.1 Specialized Management Clinic for Psychosocial Support
Participants who did not have access to a specialized management clinic all
indicated that they would be interested in attending such a clinic if one were to be
established in the Midlands region. The study sought to identify current practices and
resources that these participants utilize, as well as their preferences for the setup of a
specialized management clinic in the future. Participants currently utilize online support
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groups as well as family members who also are at increased risk for developing cancer as
a support resource, relying on these individuals not only for psychological support, but
also as a source of information regarding risk and risk-reduction.
Mahon (2014) found that previvors often feel isolated, as if no one else
understands what they are going through and “different from those who do not carry a
mutation” (Mahon, 2014, p. 22). Study participants, like the participant that joined a
Facebook group, expressed similar feelings to that found by Mahon. These findings
indicate that a psychosocial support aspect to a specialized clinic may also be beneficial.
Leaning into a support community allowed for not only psychological support,
but also further information and education regarding cancer risk and current research.
However, despite the benefits gained from the previvor community, Prisma HealthMidlands Participant 1 also expressed concerns with the contrasting information shared
within the group, sharing that that some Facebook users had certain perceptions regarding
associated cancer risks while others held different perceptions. This experience suggests
that support groups may be beneficial for encouragement and learning from other
previvors but may not be the most appropriate place for effective education.
In terms of psychological health, numerous participants with access to the
Genetics Management Clinic described how the management clinic helped reduce their
levels of stress (Genetics Management Clinic Participants 1, 4, & 5, High-Risk Breast
Lifetime Clinic Participant 5). Genetics Management Clinic Participant 5 described how
the process “can be overwhelming, and they make it manageable.” High-Risk Breast
Lifetime Clinic Participant 5 shared how the clinic helped provide peace of mind and
reduction of anxiety. Genetics Management Clinic Participant 1 felt that she was
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confident that she was doing everything to prevent the return of cancer, and Genetics
Management Clinic Participant 4 echoed this sentiment, describing how the clinic helped
make the process a lot easier and less stressful.
2.5.2 Specialized Management Clinic for Healthcare Needs
Previvors without access to a specialized management clinic often rely on their
current healthcare providers (primary care physicians, OB/GYNs, etc.) for care related to
their increased cancer risk. Review of the literature suggests that these healthcare
providers often lack the confidence regarding management guidelines to effectively care
for these patients (Dekanek et. al., 2019). In fact, Dekanek and colleagues (2019)
surveyed 86 OB/GYN and family practice physicians and found that only 44% of
providers surveyed felt somewhat confident in discussing BRCA management guidelines,
and no providers felt completely confident in doing so.
Participants in our study were asked to rank their agreement with the following
statement: “I feel that my healthcare providers (primary care physician, obstetrician,
gynecologist, etc.) have expert knowledge about the cancer screenings recommended for
me” (Prisma Health-Midlands Survey). No participants indicated that they strongly
agreed with the statement, further supporting previous literature that suggests that
healthcare providers may require additional education about hereditary cancer and
familial cancer and how to care for these patients. This finding again points to the need
for a specialized management clinic, with providers who have expert knowledge in
genetics and previvorship.
A study by Dean and Davidson (2018) discussed how previvors cope with
uncertainty related to their increased risk for cancer and how they navigate care. One
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common theme they identified among previvors was feeling that their experiences with
healthcare providers were overwhelming. This feeling was not simply due to the
management recommendations associated with the visit but also connected with the fact
that previvors are sometimes burdened with the task of educating the provider about their
risk and management (Dean & Davidson, 2018). Prisma Health-Midlands Participant 3
experienced this lack of provider education and described how challenging it was to
broach the subject with her physician because she felt it was uncomfortable to question
the authority of a physician. In this study, one previvor encountered a healthcare provider
who did not understand her perception of her cancer risk which left her feeling
invalidated when she asked her physician about the possibility of a risk-reducing
mastectomy. While there was one participant that felt comfortable with the care given by
their healthcare provider, this was not the majority opinion. Therefore, these experiences
highlight previvors’ need to advocate for themselves in the healthcare community,
standing up for the care that they need.
Participants with access to a specialized management clinic (either the Genetics
Management Clinic or High-Risk Breast Lifetime Clinic) expressed high levels of
satisfaction with their experience at the clinic, especially in regard to the simplicity of the
care they received. Although receiving the initial risk assessment and management plan
can be quite overwhelming, participants expressed that once established in the clinic, care
became much easier. Goh and Spiegelman (2020) found that scheduling difficulties were
a major factor prohibiting previvors’ proper adherence to the management guidelines. By
establishing a specialized management clinic, this barrier was reduced (if not eliminated)
with all coordination of appointments for screening or clinical evaluation being handled
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by one clinic. Other studies found that insurance coverage for surveillance was a barrier
to adherence; however, our participants did not express concerns with insurance
coverage, possibly due to the coordination of the management clinic (Dean et. al., 2017).
A specialized management clinic would include psychosocial support,
management information, and updates on genetics. All six participants from the Prisma
Health-Midlands clinic indicated they would be interested in attending a specialized
management clinic for previvors if one were to be established. Although exact logistical
details will depend on clinic staffing and location-dependent requirements, participants
indicated several important services to be included in a management clinic. These
integral features included access to a specialist with expertise in genetics, a system in
place to be notified of changes to risk or management, and a place where previvors can
ask questions.
Participants described the need for a specialist in genetics and oncology to be
involved in their care (Prisma Health-Midlands Participants 3 & 4), as Prisma HealthMidlands Participant 3 sought access to providers who understood risks specific to her
genetic mutation. This desire for a specialist’s involvement in a management clinic may
again relate back to the fact that general practitioners may not be confident in providing
care to previvors and, as a result, previvors’ care may not be sufficiently attended to
(Dekanek et. al., 2019). This likely is of no fault of general practitioners but may stem
from inadequate provider education regarding hereditary cancer and familial risks that
reduces the confidence of these healthcare workers. A dedicated clinic for these
individuals could provide a solution to a lack of access to educated providers without the
need to provide mass education.
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This benefit was observed in our study with those who have access to a
specialized management clinic. The patients were able to be seen for care quickly by
multiple different providers, and any delay in care was prevented as much as possible.
Genetics Management Clinic Participant 4 explained that she probably would have gone
to different providers (breast, gastroenterology, etc.) in a prioritized manner over a period
of time, but that it would not have been expedited like it was in the Genetics Management
Clinic. Once theoretical plans have been put into action by the management clinic,
previvors begin their journey towards cancer prevention and risk-reduction.
In addition to desiring a thorough education from someone who understands their
exact mutation, participants also seek a clinic organized in such a way that they will be
notified of any important changes to their risk status. As the genetics behind hereditary
cancer continue to be researched, cancer risks and management recommendations may be
updated. The NCCN publishes updated guidelines for genetic and familial high-risk care
on a regular basis, often updating minor details, but occasionally altering cancer risk
estimates or recommended screening strategies or risk-reduction methodology (NCCN,
2020). Other research studies or clinical trials may offer specific information for
previvors that individuals may not have access to on their own but would value learning
about from a trusted healthcare provider. Prisma Health-Midlands Participant 1 described
access to research as a major benefit of the CHEK2 Facebook group. It is possible that
access to such research shared by a healthcare provider may be of even greater benefit if
coupled with a simplified explanation.
Lastly, participants desired a clinic that gave them the opportunity to ask
questions about their cancer risks and recommended management. Logistical questions
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about screening, risk-reducing surgeries, and providers familiar with genetics were
common concerns of participants. For example, one participant was interested in more
information about recommended providers or clinics and where to go for care (Prisma
Health-Midlands Participant 1). Although there are many factors that influence a patient’s
care choices (for example, age, parental status, level of psychological distress, perceived
family support, experienced medical uncertainty), patients require a clinic staffed with a
provider able to answer their questions and assist in facilitating decision-making with
these factors taken into account (Hesse-Biber & An, 2016).
Participants of the Genetics Management Clinic and High-Risk Breast Lifetime
Clinic felt that they were provided all information needed to make informed decisions
regarding their care. Cancer prevention and risk-reduction comes with many nuances and
options, which participants appreciated the opportunity to discuss with a specialized
provider. When asked about the most valuable service provided by the clinic, Genetics
Management Clinic Participant 5 stated:
Education about the gene mutations as related to what it means and actions to take
that can reduce your risk. I felt I could be proactive in reducing my cancer risks
and that gave me some sense of control and a plan. After having my world turned
upside down with a cancer diagnosis that was very helpful to me. (Genetics
Management Clinic Participant 5)
Providers in the clinic could help patients balance logical and emotional decision-making
styles and assist the patient in coming to a decision they are satisfied with (Dean &
Rauscher, 2017). For example, the provider could discuss the options of risk-reducing
mastectomy or oophorectomy, and the potential effects it could have on patient quality of
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life and family dynamics in addition to lowering cancer risks (Alexandre et. al., 2017;
Mahon, 2014). By having expert providers provide these services in place of the patient’s
primary care physician or OB/GYN, general practitioners have reduced burden for
counseling patients on risks and management they are not confident of, and patients
receive care catered specifically to their needs (Dekanek et. al., 2019).
2.5.3 Role of a Genetic Counselor
Although not specifically seeking to look at patient satisfaction with genetic
counseling, this study found that participants were highly satisfied with the level of
information provided to them by genetics professional. Many participants first learned of
their previvor status from a genetic counselor, and participants expressed the benefits of
meeting with a genetic counselor. Participants indicated that they felt supported
throughout the testing process and were pleased with the information provided to them by
their genetic counselor, stating that it helped them feel more prepared and increased their
ability to be proactive regarding their risk.
This high satisfaction with genetic counselors echoes previous research on patient
satisfaction with genetic counseling (Sagi et. al., 1998). After genetic counseling, patients
better understood the link between genetics and cancer, received answers to their
questions, and felt confident in their plan for follow-up (Sagi et. al., 1998). Genetic
counselors’ ability to break down complex scientific material in layman’s terms, coupled
with a focus on psychosocial considerations associated with hereditary cancer testing,
allows for increased patient satisfaction. Although participants were highly satisfied with
their initial genetic counseling visit, it is evident from the survey responses that patients
would like additional follow-up regarding their high-risk status, whether due to family
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history or a genetic mutation. This supports the role of a genetic counselor in a
specialized management clinic.
2.6 Study Limitations
A major limitation of this study is the lack of participants who responded to the
survey invitations and semi-structured phone interviews. Possible explanations for this
may be due to the nature of sending research study invitations by mail, especially
considering participants had no notification prior to receiving a letter that they would be
contacted. Furthermore, it is possible that patients who are several years out from their
initial appointment with the genetic counselor would be less interested in participating in
the study if they already have a management plan in place. Additionally, the majority of
participants with hereditary cancer mutations carried a variant in either BRCA1 or
BRCA2, the two genes in the study with the highest lifetime risk for breast cancer. It is
possible that this sample is biased towards desiring a clinic due to their substantially
increased risk, as individuals of the clinics with variants in genes with lower risk chose
not to participate. It is however possible, that this finding could be due to mutations in
these genes being the most common finding on hereditary breast cancer panels and
clinical testing for these genes having been available for longer, implying more patients
may have been identified with BRCA1 or BRCA2 variants.
2.7 Future Research
Further research is needed in the area of previvorship and the establishment and
utility of specialized management clinics, particularly studying patient adherence to
clinical guidelines once a patient is seen in a management clinic, exploring patient health
outcomes of previvors within these clinics, and further exploration of the clinic model for
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previvors with hereditary cancer syndromes associated with cancers other than breast
cancer.
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CHAPTER 3: CONCLUSIONS
This study explored patient satisfaction and approach to care for previvors with
access to a specialized management clinic and for those without access. Overall, all
participants without access to a management clinic desired the establishment of one in the
Midlands region, particularly with the hope of connecting with a specialist in genetics,
being notified of changes to cancer risks or management recommendations, and having
an opportunity to get questions answered. Participants described their current framework
of care which largely included online support groups, guidance from their general
practitioner, and the need for self-advocacy within both the healthcare realm and with
their family, friends, and society. In contrast, participants who had access to a
management clinic, such as the Genetics Management Clinic or High-Risk Breast
Lifetime Clinic expressed high levels of satisfaction with their care. These participants
cited a simplified and efficient process, prevention of delay to care, access to all
information needed to make informed decisions, and reduced stress as major benefits of
the management clinic. Specialized management clinics are not only helpful in guiding
patients and allowing unhindered access to resources and support, but it improves the
overall psychological health of the patient, which may lead to better health outcomes.
These findings further point to the necessity of specialized management clinics, specific
to the needs of previvors in order to improve patient care and overall wellbeing.
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APPENDIX A: RECRUITMENT LETTER FOR
PRISMA HEALTH-MIDLANDS PARTICIPANTS
Dear Patient,
You are receiving this letter because you underwent cancer genetic counseling with Prisma
Health-USC Genetic Counseling, and we are interested in creating a clinic that could assist in
your healthcare. We are looking into the development of a clinic that would allow individuals
with an increased risk of cancer to be seen by one healthcare practitioner who would oversee
all the screening required because of that risk. To assess patient interest in this service, we are
asking former patients to complete a survey. Through the information collected, we hope to
provide better care for our patients.
The study involves completing an online survey. At the completion of the survey, you will be
given the option for a follow-up telephone interview. The survey is available online through
Qualtrics and should take no more than 15 minutes to complete. The survey involves
questions about your understanding of your predisposition for cancer, how you are currently
receiving care, and your level of interest in the establishment of a new clinic for your cancer
management. Participation is completely confidential. Data from the study will be stored in a
secure location, will not be placed in your health record nor linked to your name, and will be
destroyed at the completion of the study. The phone interviews will be recorded for analysis
by the research team, but all information that you provide will be kept confidential. The
results of the study may be published or presented; however, your identity will remain
anonymous. This study is completely voluntary, and there are no negative consequences
should you withdraw from the study.
This study is a University of South Carolina Master in Genetic Counseling student thesis
project. Maddie Tjoelker is completing her master’s degree and is conducting research on
how individuals with a family history of cancer access screening and management.
If you are interested in taking this survey, please enter the following link into your internet
browser on your computer, smart phone, or tablet. You may also scan the QR link to access
the survey.
Link: https://uofsc.co1.qualtrics.com/jfe/form/SV_3PD56T5ogQ2101
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Your involvement in this study will help healthcare providers best serve their patients and
give easier access to much-needed services. If you have any questions regarding the study or
trouble accessing the survey, please reach out to myself or to Maddie Tjoelker. Thank you for
your consideration.
Sincerely,
[GENETIC COUNSELOR], MS, CGC
[PHONE NUMBER]
[EMAIL ADDRESS]

Maddie Tjoelker
(803) 386-7302
Madeleine.Tjoelker@uscmed.sc.edu
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APPENDIX B: RECRUITMENT LETTER FOR PRISMA HEALTH-UPSTATE
GENETICS MANAGEMENT CLINIC PARTICIPANTS
Dear Patient,
You are receiving this letter because you have been seen at the Prisma Health Genetics
Management Clinic, and we are interested in hearing your feedback. To assess patient
satisfaction in this service, we are asking patients to complete a survey. Through the
information collected, we hope to provide better care for our patients.
The study involves completing an online survey. At the completion of the survey, you
will be given the option for a follow-up telephone interview. The survey is available
online through Qualtrics and should take no more than 15 minutes to complete. The
survey involves questions about your understanding of your predisposition for cancer,
how you are currently receiving care, and your level of satisfaction in the care you have
received at the Genetics Management Clinic. Participation is completely confidential.
Data from the study will be stored in a secure location, will not be placed in your health
record nor linked to your name, and will be destroyed at the completion of the study. The
phone interviews will be recorded for analysis by the research team, but all information
that you provide will be kept confidential. The results of the study may be published or
presented; however, your identity will remain anonymous. This study is completely
voluntary, and there are no negative consequences should you withdraw from the study.
This study is a University of South Carolina Master in Genetic Counseling student thesis
project. Maddie Tjoelker is completing her master’s degree and is conducting research on
how individuals with a family history of cancer access screening and management.
If you are interested in taking this survey, please enter the following link into your
internet browser on your computer, smart phone, or tablet. You may also scan the QR
link to access the survey.
Link: https://uofsc.co1.qualtrics.com/jfe/form/SV_8kzMhuAwTTLyQ9D
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Your involvement in this study will help healthcare providers best serve their patients and
give easier access to much-needed services. If you have any questions regarding the study
or trouble accessing the survey, please reach out to myself or to Maddie Tjoelker. Thank
you for your consideration.
Sincerely,
LeAnn Perkins, MSN, FNP-BC
(864) 455-1346

Maddie Tjoelker
(803) 386-7302
Madeleine.Tjoelker@uscmed.sc.edu

60

APPENDIX C: RECRUITMENT LETTER FOR PRISMA HEALTH-UPSTATE
HIGH-RISK BREAST LIFETIME CLINIC PARTICIPANTS
Dear Patient,
You are receiving this letter because you have been seen at the Prisma Health High-Risk
Breast Lifetime Clinic, and we are interested in hearing your feedback. To assess patient
satisfaction in this service, we are asking patients to complete a survey. Through the
information collected, we hope to provide better care for our patients.
The study involves completing an online survey. At the completion of the survey, you
will be given the option for a follow-up telephone interview. The survey is available
online through Qualtrics and should take no more than 15 minutes to complete. The
survey involves questions about your understanding of your predisposition for cancer,
how you are currently receiving care, and your level of satisfaction in the care you have
received at the High-Risk Breast Lifetime Clinic. Participation is completely confidential.
Data from the study will be stored in a secure location, will not be placed in your health
record nor linked to your name, and will be destroyed at the completion of the study. The
phone interviews will be recorded for analysis by the research team, but all information
that you provide will be kept confidential. The results of the study may be published or
presented; however, your identity will remain anonymous. This study is completely
voluntary, and there are no negative consequences should you withdraw from the study.
This study is a University of South Carolina Master in Genetic Counseling student thesis
project. Maddie Tjoelker is completing her master’s degree and is conducting research on
how individuals with a family history of cancer access screening and management.
If you are interested in taking this survey, please enter the following link into your
internet browser on your computer, smart phone, or tablet. You may also scan the QR
link to access the survey.
Link: https://uofsc.co1.qualtrics.com/jfe/form/SV_0pPw6LTin4WbKDP
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Your involvement in this study will help healthcare providers best serve their patients and
give easier access to much-needed services. If you have any questions regarding the study
or trouble accessing the survey, please reach out to myself or to Maddie Tjoelker. Thank
you for your consideration.
Sincerely,
LeAnn Perkins, MSN, FNP-BC
(864) 455-1346

Maddie Tjoelker
(803) 386-7302
Madeleine.Tjoelker@uscmed.sc.edu
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APPENDIX D: SURVEY QUESTIONS FOR
PRISMA HEALTH-MIDLANDS PARTICIPANTS
Thank you for your participation in our study. All responses will be kept confidential and
anonymous. In order to begin the survey, please indicate whether you consent to
participating in our study.
a. I consent
b. I do not consent
1. Please select your gender
a. Male
b. Female
c. Prefer not to answer
2. Please select your age from the following ranges:
a. 18-25
b. 26-30
c. 31-40
d. 41-50
e. 51-60
f. 61-70
g. Over 70
3. Do you carry a positive mutation in a hereditary cancer gene?
a. Yes
b. No
FOR MUTATION-POSITIVE PARTICIPANTS
4. If yes, which gene?
5. Have you been diagnosed with cancer?
a. Yes
b. No
Please rate the following statements:
6. I feel I have adequate knowledge about my cancer risk and am able to manage my
personal healthcare to meet the recommendations.
a. Strongly disagree
b. Somewhat disagree
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c. Neither agree nor disagree
d. Somewhat agree
e. Strongly agree
Comments on Question 6:
7. I feel that my healthcare providers (primary care physician, obstetrician, gynecologist,
etc.) have expert knowledge about the cancer screenings recommended for me.
a. Strongly disagree
b. Somewhat disagree
c. Neither agree nor disagree
d. Somewhat agree
e. Strongly agree
Comments on Question 7:
8. I have difficulty getting insurance coverage for the recommended cancer screenings.
a. Strongly disagree
b. Somewhat disagree
c. Neither agree nor disagree
d. Somewhat agree
e. Strongly agree
Comments on Question 8:
9. Some institutions have set up clinics designed to assist individuals who carry a positive
mutation in a hereditary cancer gene get the recommended screenings and management.
How interested would you be in attending this clinic if it were created at Prisma Health
Richland?
a. Not at all interested
b. Likely not interested
c. Neutral
d. Somewhat interested
e. Very interested
10. Click and drag the following selections to rank the following services based on how
important their incorporation into such a clinic is to you, with 1 being most important and
6 being least important.
• Cancer screenings (mammograms, breast MRI, etc.)
• Psychosocial support
• Genetic counseling
• Nutritional services
• Oncology
• Plastic surgery
11. Are there any additional services you would like to be included in this clinic?
12. How often would you want to attend this type of clinic?
a. Only once
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b. Every 5 years
c. Every 2 years
d. Every year
e. Every 6 months
f. Other (please specify)
13. Based on this conversation, what other thoughts do you have regarding the
establishment of this type of clinic?
FOR HIGH-RISK PARTICIPANTS
4. Have you been diagnosed with cancer?
a. Yes
b. No
5. Have you ever been told that you are at high risk for breast cancer?
a. Yes
b. No
c. Not sure
6. Have you ever been told to do more breast cancer screening than an annual
mammogram (such as breast MRI annually)?
a. Yes
b. No
c. Not sure
Please rate the following statements:
7. I feel I have adequate knowledge about my cancer risk and am able to manage my
personal healthcare to meet the recommendations.
a. Strongly disagree
b. Somewhat disagree
c. Neither agree nor disagree
d. Somewhat agree
e. Strongly agree
Comments on Question 7:
8. I feel that my healthcare providers (primary care physician, obstetrician, gynecologist,
etc.) have expert knowledge
a. Strongly disagree
b. Somewhat disagree
c. Neither agree nor disagree
d. Somewhat agree
e. Strongly agree
Comments on Question 8:
9. I have difficulty getting insurance coverage for the recommended cancer screenings.
a. Strongly disagree
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b. Somewhat disagree
c. Neither agree nor disagree
d. Somewhat agree
e. Strongly agree
Comments on Question 9:
10. Some institutions have set up clinics designed to help individuals who are at a higher
risk for developing breast cancer get the recommended screenings. How interested would
you be in attending this clinic if it were created at Prisma Health Richland?
a. Not at all interested
b. Likely not interested
c. Neutral
d. Somewhat interested
e. Very interested
Comments on Question 10:
11. Click and drag the following selections to rank the following services based on how
important their incorporation into such a clinic is to you, with 1 being most important and
6 being least important.
• Cancer screenings (mammograms, breast MRI, etc.)
• Psychosocial support
• Genetic counseling
• Nutritional services
• Oncology
• Plastic surgery
12. Are there any other services that you would want to be offered at this clinic?
13. How often would you want to attend this type of clinic?
a. Only once
b. Every 5 years
c. Every 2 years
d. Every year
e. Every 6 months
f. Other (please specify)
14. Based on this conversation, what other thoughts do you have regarding the
establishment of this type of clinic?
FOR BOTH GROUPS: [At the completion of the survey] We want to hear more about
your personal experience getting care and your level of interest in the establishment of
this new clinic. If you would be willing to complete a follow-up telephone interview with
Maddie Tjoelker, the primary investigator on this project, please fill in your telephone
number below, otherwise enter N/A to complete the survey.
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APPENDIX E: SURVEY QUESTIONS FOR PRISMA HEALTH-UPSTATE
GENETICS MANAGEMENT CLINIC PARTICIPANTS
Thank you for your participation in our study. All responses will be kept confidential and
anonymous. In order to begin the survey, please indicate whether you consent to
participating in our study.
a. I consent
b. I do not consent
1. Do you carry a positive mutation in a hereditary cancer gene?
a. Yes
b. No
2. If yes, what gene?
a. ATM
b. BRCA1
c. BRCA2
d. CDH1
e. CHEK2
f. PALB2
g. PTEN
h. TP53
3. When did you have genetic testing?
a. Less than 6 months ago
b. 6-12 months ago
c. 12-18 months ago
d. 18-24 months ago
e. Over 24 months ago
4. When did you first begin attending the Genetics Management Clinic?
a. Less than 6 months ago
b. 6-12 months ago
c. 12-18 months ago
d. 18-24 months ago
e. Over 24 months ago
5. Have you been diagnosed with cancer (not including non-melanoma skin cancer)?
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a. Yes
b. No
6. On a scale from 1-10, with 1 being not at all satisfied and 10 being very satisfied,
how satisfied are you with the services from the Genetics Management Clinic?
7. Has getting screenings for your cancer risk gotten easier since going to the
Genetics Management Clinic?
a. Yes
b. No
c. Not sure
Comments on Question 7:
8. How often do you attend the Genetics Management Clinic?
a. Less than once a year
b. Once a year
c. More than once a year
9. Do you feel this is too often or not enough?
10. What do you think is the most valuable service provided by the Genetics
Management Clinic?
11. Would you recommend this clinic to others?
12. Is there anything that you wish would be added to the offerings of this clinic?
(e.g., psychology, nutrition, etc.)
[At completion of the survey] We want to hear more about your personal experience
getting care at the Genetics Management Clinic. If you would be willing to complete a
follow-up telephone interview with Maddie Tjoelker, the primary investigator on this
project, please fill in your telephone number below, otherwise enter N/A to complete the
survey.
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APPENDIX F: SURVEY QUESTIONS FOR PRISMA HEALTH-UPSTATE
HIGH-RISK BREAST LIFETIME CLINIC PARTICIPANTS
Thank you for your participation in our study. All responses will be kept confidential and
anonymous. In order to begin the survey, please indicate whether you consent to
participating in our study.
a. I consent
b. I do not consent
1. When did you first begin attending the High-Risk Breast Lifetime Clinic?
a. Less than 6 months ago
b. 6-12 months ago
c. 12-18 months ago
d. 18-24 months ago
e. More than 24 month ago
2. What made you decide to attend the High-Risk Breast Lifetime Clinic?
3. How often do you attend this clinic?
a. Every 3 months
b. Every 6 months
c. Every 12 months
d. Every 18 months
e. Every 24 months
f. Other (please specify)
4. On a scale from 1-10, with 1 being not at all satisfied and 10 being very satisfied,
how satisfied are you with the services provided by the High-Risk Breast Lifetime
Clinic?
5. Has getting mammograms and breast MRIs gotten easier since attending this clinic?
a. Yes
b. No
c. Not sure
Comments on Question 5:
6. What do you think is the most valuable service provided by the High-Risk Breast
Lifetime Clinic?
7. Is there anything that you wish would be added to the offerings of this clinic?
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[At completion of the survey] We are interested in hearing more about your personal
experience with the High-Risk Breast Lifetime Clinic. If you would be willing to
complete a follow-up telephone interview with Maddie Tjoelker, the primary investigator
on this project, please fill in your telephone number below, otherwise enter N/A to
complete the survey.
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APPENDIX G: PRISMA HEALTH-MIDLANDS SERVICE PREFERENCES
Table G.1 Service Preferences Frequencies
FREQUENCIES
SERVICE
RANK
1 2 3 4 5 6
Cancer
5 1 0 0 0 0
Screenings
Psychological 0 0 1 1 2 2
Support
Genetic
1 3 1 0 0 1
Counseling
Nutritional
0 1 2 2 0 1
Services
Oncology
0 1 1 2 1 1
Plastic
Surgery

0 0

1

1 3 1

Table G.2 Ranked Service Preferences
OVERALL RANKING
Total
Rank
Cancer Screenings
35
1
Psychological
14
6
Support
Genetic Counseling
26
2
Nutritional Services
20
3
Oncology
18
4
Plastic Surgery
14
5
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Ranked Preferences of Services Midlands
40
35
30
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Figure G.1 Ranked Preferences of Services-Midlands
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Oncology

Plastic Surgery

APPENDIX H: GENETICS MANAGEMENT CLINIC PARTICIPANT DATA
Table H.1 Genetics Management Clinic Participant Data
Clinical Information and Attendance
N
Frequency
When did you have genetic testing?
Less than 6 months ago
0
0%
6-12 months ago
1
10%
12-18 months ago
1
10%
18-24 months ago
3
30%
Over 24 months ago
5
50%
When did you first begin attending the Genetics Management Clinic?
Less than 6 months ago
0
0%
6-12 months ago
1
10%
12-18 months ago
1
10%
18-24 months ago
4
40%
Over 24 months ago
4
40%
Have you been diagnosed with cancer? (Not including non-melanoma skin cancer)
Yes
6
60%
No
4
40%
Has getting screenings for your cancer risk gotten easier since going to the Genetics
Management Clinic?
Yes
5
50%
No
0
0%
Not sure
5
50%
How often do you attend the Genetics Management Clinic?
Less than once a year
1
10%
Once a year
9
90%
More than once a year
0
0%
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APPENDIX I: HIGH-RISK BREAST LIFETIME CLINIC PARTICIPANT DATA
Table I.1 High-Risk Breast Lifetime Clinic Participant Data
Clinical Information and Attendance
N
Frequency
When did you first begin attending the High-Risk Breast Lifetime Clinic?
Less than 6 months ago
0
0%
6-12 months ago
1
11.1%
12-18 months ago
2
22.2%
18-24 months ago
1
11.1%
Over 24 months ago
5
55.6%
How often do you attend the High-Risk Breast Lifetime Clinic?
Every 6 months
4
50%
Every 12 months
3
37.5%
Other—No longer attend
1
12.5%
On a scale from 0-10, with 0 being not at all satisfied and 10 being very satisfied, how
satisfied are you with the services provided by the High-Risk Breast Lifetime Clinic?
1
0
0%
2
0
0%
3
0
0%
4
0
0%
5
0
0%
6
0
0%
7
2
22.2%
8
2
22.2%
9
2
22.2%
10
3
33.3%
Has getting breast cancer screening (i.e., mammograms and breast MRIs) gotten easier
since attending this clinic?
Yes
6
66.7%
No
2
22.2%
Not sure
1
11.1%
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